Sage Therapeutics’ SAGE-217 fails in late-stage depression trial
Sage Therapeutics is developing SAGE-217 for the treatment of depression. Credit: ryan melaugh.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more